Levothyroxine sodium


Generic Medicine Info
Administration
Levothyroxine sodium: Should be taken on an empty stomach. Take 30 min - 1 hr before meals.
Contraindications
Untreated hyperthyroidism; uncorrected adrenal insufficiency; acute MI.
Special Precautions
Patients w/ CV (e.g. angina, heart failure, HTN), DM and diabetes insipidus, epilepsy, pre-existing myasthenia syndrome, long-standing hypothyroidism. Elderly, pregnancy and lactation. Monitoring Parameters Monitor thyroid function test, clinical signs of hypo- and hyperthyroidism, heart rate and BP.
Adverse Reactions
Nervousness, excitability, tremor, muscle weakness, fatigue, cramps; sweating, flushing, heat intolerance, headache, fever, insomnia, tachycardia, palpitations, restlessness, anginal pain, HTN, severe depression, difficulty in sleeping, excessive wt loss; menstrual irregularities; diarrhoea, vomiting, psychosis or agitation. Increased bone resorption and reduced bone mineral density, especially in post-menopausal women; elevated LFT.
Potentially Fatal: Thyrotoxic crisis including convulsions, cardiac arrhythmia, heart failure, coma.
Drug Interactions
Reduced absorption w/ iron, antacids, bile acid sequestrants, colestyramine, simeticone, Ca carbonate, sucralfate, cation exchange resins. Reduced tri-iodothyronine serum levels w/ amiodarone and propranolol. Reduced serum levels of thyroxine w/ carbamazepine, phenytoin, phenobarbital, rifampicin, lithium, oestrogens, sertraline. Androgens may decrease levothyroxine-binding globulins serum levels. May alter requirements of antidiabetic drugs. Increased risk of significant HTN and tachycardia w/ ketamine. Increased metabolic demands w/ sympathomimetics (e.g. epinephrine). May increase anticoagulant effect of warfarin.
CIMS Class
ATC Classification
H03AA01 - levothyroxine sodium ; Belongs to the class of thyroid hormones.
Disclaimer: This information is independently developed by CIMS based on levothyroxine sodium from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in